Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000102 · ClinicalTrials.gov registry record
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 14
- Enrollment target
NCT02000102: Completed study, sponsored by Stanford University.
NCT02000102 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000102 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
Interventions
- DRUG Intravitreal Injection of Aflibercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-09 |
| Est. Completion | 2014-09 |
What the finished NCT02000102 record still lists
NCT02000102 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal Injection of Aflibercept is the first listed.
NCT02000102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02000102 about?
NCT02000102 is a clinical study titled "Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab". Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
What is the current status of trial NCT02000102?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2013-09. Estimated completion is 2014-09.
What interventions are being tested in trial NCT02000102?
The interventions under investigation include: Intravitreal Injection of Aflibercept (DRUG).
Who is sponsoring clinical trial NCT02000102?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia